tradingkey.logo
搜索

CVRx Inc

CVRX
添加自选
5.600USD
+0.100+1.82%
收盘 07/02, 13:00美东报价延迟15分钟
148.00M总市值
亏损市盈率 TTM

CVRx Inc

5.600
+0.100+1.82%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.82%

5天

-4.44%

1月

-4.76%

6月

-21.13%

今年开始到现在

-21.13%

1年

-14.89%

关键数据
5.580今开
5.750最高
149.55K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.57%换手率
5.500昨收
5.460最低
643.71K成交额
亏损市盈率静
5.08市净率
0.00%股息率 TTM
-45.93%ROA
11.30052周最高
0.62量比
-59.97M净利润
26.43M总股本
-2.0094每股收益TTM
0.79Beta
-106.96%ROE
4.37052周最低
5.27%振幅
87.22%毛利率
148.00M总市值
-1.34回报/风险
4.81%风险率

TradingKey CVRx Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

CVRx Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名106/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价12.25。中期看,股价处于下降通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

CVRx Inc评分

相关信息

行业排名
106 / 204
全市场排名
254 / 4565
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

CVRx Inc亮点

亮点风险
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
业绩高增长
公司营业收入稳步增长,连续3年增长44.17%
业绩增长期
公司处于发展阶段,最新年度总收入56.65M美元
利润高增长
公司净利润处于行业前列,最新年度总收入56.65M美元
估值高估
公司最新PE估值-2.79,处于3年历史高位
机构减仓
最新机构持股17.25M股,环比减少15.08%

分析师目标

根据 7 位分析师
买入
评级
12.250
目标均价
+122.73%
涨幅空间

CVRx Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

CVRx Inc简介

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
公司代码CVRX
公司CVRx Inc
CEOHykes (Kevin)
网址https://www.cvrx.com/

常见问题

CVRx Inc(CVRX)的当前股价是多少?

CVRx Inc(CVRX)的当前股价是 5.60。

CVRx Inc的股票代码是什么?

CVRx Inc的股票代码是CVRX。

CVRx Inc股票的52周最高点是多少?

CVRx Inc股票的52周最高点是11.30。

CVRx Inc股票的52周最低点是多少?

CVRx Inc股票的52周最低点是4.37。

CVRx Inc的市值是多少?

CVRx Inc的市值是147.34M。

现在CVRx Inc(CVRX)的股票是买入、持有还是卖出?

根据分析师评级,CVRx Inc(CVRX)的总体评级为买入,目标价格为12.25。

CVRx Inc(CVRX)股票的每股收益(EPS TTM)是多少

CVRx Inc(CVRX)股票的每股收益(EPS TTM)是-2.04。